Item 2.02 Results of Operations and Financial Condition.

On January 5, 2021, Mersana Therapeutics, Inc. (the "Company") issued a press release announcing corporate and pipeline updates and 2021 goals and anticipated milestones. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The Company is also furnishing, as Exhibit 99.2 to this Current Report on Form 8-K, an analyst and investor presentation, which the Company intends to use on January 5, 2021 in connection with a presentation to the investment community (the "Analyst Presentation").

The information included in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.




 Item 8.01 Other Events.

The Company is filing the Analyst Presentation as Exhibit 99.2 to this Current Report on Form 8-K, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.



Exhibit No.                                   Description

  99.1                   Press release issued by Mersana Therapeutics, Inc. on
                       January 5, 2021
  99.2                   Analyst & Investor Presentation, dated January 5,
                       2021
104                    The cover page from this Current Report on Form 8-K,
                       formatted in Inline XBRL

© Edgar Online, source Glimpses